GoalVest Advisory LLC Buys New Stake in Cardiff Oncology, Inc. $CRDF

GoalVest Advisory LLC bought a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 687,285 shares of the company’s stock, valued at approximately $832,000. GoalVest Advisory LLC owned 0.88% of Cardiff Oncology as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in CRDF. BlackRock Inc. purchased a new position in Cardiff Oncology during the 2nd quarter valued at about $1,265,000. Glenview Trust Co purchased a new stake in Cardiff Oncology during the second quarter worth about $56,000. Capstone Investment Advisors LLC acquired a new stake in shares of Cardiff Oncology during the second quarter worth about $67,000. Hsbc Holdings PLC acquired a new stake in shares of Cardiff Oncology during the second quarter worth about $37,000. Finally, Ieq Capital LLC purchased a new position in shares of Cardiff Oncology in the second quarter valued at approximately $58,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Cardiff Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 22nd. Wall Street Zen raised shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th. William Blair downgraded shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright raised Cardiff Oncology from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 15th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.50.

Cardiff Oncology Price Performance

Shares of CRDF stock traded down $0.06 during trading hours on Friday, reaching $1.12. 226,864 shares of the stock were exchanged, compared to its average volume of 1,121,609. The business’s fifty day moving average is $1.06 and its two-hundred day moving average is $1.36. Cardiff Oncology, Inc. has a 12-month low of $0.76 and a 12-month high of $3.31. The firm has a market capitalization of $87.51 million, a P/E ratio of -1.87 and a beta of 1.42.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%.The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.06 million. As a group, equities research analysts predict that Cardiff Oncology, Inc. will post -0.6 earnings per share for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth.

Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer.